PRKRA and Dystonia: The lear-5J mouse model (Palmer et al., 2016) of DYT-PRKRA will be very useful for characterizing the contribution of ISR dysregulation to dystonia phenotype, evaluating luteolin as a therapeutic agent, and determining therapeutic windows in which luteolin mediated ISR modulation could prove beneficial.